Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Wave Life Sciences ( (WVE) ) has issued an announcement.
On May 18, 2026, Wave Life Sciences reported updated data from its ongoing RestorAATion-2 Phase 1b/2a trial of WVE-006, an investigational GalNAc-conjugated RNA editing therapy for alpha-1 antitrypsin deficiency, showing that both biweekly 200 mg and monthly 400 mg dosing regimens achieved an MZ-like protective phenotype. The therapy generated substantial levels of wild-type M-AAT, reduced toxic Z-AAT by about 70%, restored dynamic AAT production during acute phase responses, and demonstrated sustained editing with a favorable safety profile, underscoring its potential to become a differentiated, convenient standard of care for both lung and liver disease in AATD and to strengthen Wave’s positioning in RNA editing therapeutics.
The most recent analyst rating on (WVE) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.
Spark’s Take on WVE Stock
According to Spark, TipRanks’ AI Analyst, WVE is a Neutral.
The score is held back primarily by weak financial performance (large ongoing losses and significant cash burn) and soft technicals (below key moving averages with negative MACD). Offsetting these, the latest earnings call reflected strong operational momentum and a long cash runway supporting multiple upcoming clinical/regulatory catalysts.
To see Spark’s full report on WVE stock, click here.
More about Wave Life Sciences
Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing RNA-based medicines, including RNA editing oligonucleotides, to treat serious genetic diseases. The company’s pipeline targets conditions such as alpha-1 antitrypsin deficiency, aiming to offer convenient, subcutaneous therapies that address both liver and lung manifestations of disease.
Average Trading Volume: 4,519,219
Technical Sentiment Signal: Sell
Current Market Cap: $1.3B
For detailed information about WVE stock, go to TipRanks’ Stock Analysis page.